Effectiveness of rosuvastatin in low-density lipoprotein cholesterol lowering and National Cholesterol Education Program Adult Treatment Panel guideline III LDL-C goal attainment compared to other statins among diabetes mellitus patients: A retrospective study using an electronic medical records dataset in the United States

Current Medical Research and Opinion

Volumn 23, Issue 9, 2007, Pages 2125-2133

  Fox, Kathleen M ^a,e   Gandhi, Sanjay K ^b   Ohsfeldt, Robert L ^c   Blasetto, James W ^b   Bays, Harold E ^d  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b ASTRAZENECA   (United Kingdom)

^c TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^d LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER   (United States)

^e NONE   (United States)

Author keywords

ATP III goal attainment; Clinical practice; Diabetes mellitus; LDL C reduction; Rosuvastatin

Indexed keywords

ANTIDIABETIC AGENT; ATORVASTATIN; FLUINDOSTATIN; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; FLUOROBENZENE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PYRIMIDINE DERIVATIVE; SULFONAMIDE;

ADULT; AGED; ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; CONTROLLED STUDY; CORONARY RISK; ELECTRONIC MEDICAL RECORD; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; PRESCRIPTION; SMOKING HABIT; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; UNITED STATES; BLOOD; HYPERCHOLESTEROLEMIA; MEDICAL RECORD; MIDDLE AGED; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AGED; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FEMALE; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; MEDICAL RECORDS SYSTEMS, COMPUTERIZED; MIDDLE AGED; PYRIMIDINES; RETROSPECTIVE STUDIES; SULFONAMIDES; TREATMENT OUTCOME;

EID: 36048959846     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907X219580     Document Type: Article

References (19)

1. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97
2. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-39
3. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002;360:7-22
4. Collins R, Armitage J, Parish S, et al., Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial. Lancet 2003;361:2005-16
5. Schuster H, Barter PJ, Stender S, et al. Effects of switching statins on achievement of lipid goals: Measuring effective reductions in cholesterol using rosuvastatin therapy (MERCURY I) study. Am Heart J 2004;147:705-13
6. Goldberg RB, Mellies MJ, Sacks FM, et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analysis in the cholesterol and recurrent events (CARE) trial. Circulation 1998;98:2513-19
7. Haffner SM, Alexander CM, Cook TJ, et al. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study. Arch Intern Med 1999;159:2661-7
8. Colhoun HM, Betteridge DJ, Durrington PN, et al., CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized placebo-controlled trial. Lancet 2004;364:685-96
9. Bays HE, Abate N, Chandalia M. Adiposopathy: sick fat causes high blood sugar, high blood pressure and dyslipidemia. Future Cardiol 2005;1:39-59
10. Berne C, Siewert-Delle A, URANUS study investigators. Comparison of rosuvastatin and atorvastatin for lipid lowering in patients with type 2 diabetes mellitus: results from the URANUS study. Cardiovasc Diabetol 2005;4:7
11. Wolffenbuttel BH, Franken AA, Vincent HH, Dutch Corall Study Group. Cholesterol-lowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetes - CORALL study. J Intern Med 2005;257:531-9
12. Tuomilehto J, Leiter LA, Kallend D. A review of the efficacy of rosuvastatin in patients with type 2 diabetes. Int J Clin Pract Suppl 2004;143:30-40
13. Bullano MF, Wertz DA, Yang GW, et al. Effect of rosuvastatin compared with other statins on lipid levels and National Cholesterol Education Program goal attainment for low-density lipoprotein cholesterol in a usual care setting. Pharmacotherapy 2006;26:469-78
14. Tabachnick B, Fidell L. Using Multivariate Statistics, 5th edn, Boston: Pearson/Allyn Bacon, 2007
15. Bergenstal RM, Nag SS, Reusch JE, et al. Macrovascular risk factors in patients with diabetes: physician treatment strategies and extent of control. Endocr Pract 2005;11:172-9
16. Kirk JK, Huber KR, Clinch CR. Attainment of goals from national guidelines among persons with type 2 diabetes: a cohort study in an academic family medicine setting. N C Med J 2005;66:415-19
17. Spann SJ, Nutting PA, Galliher JM, et al. Management of type 2 diabetes in the primary care setting: a practice-based research network study. Ann Fam Med 2006;4:23-31
18. Frolkis JP. Pearce GL, Nambi V, et al. Statins do not meet expectations for lowering low-density lipoprotein cholesterol levels when used in clinical practice. Am J Med 2002;113:625-9
19. Boulanger L, Kim J, Friedman M, et al. Patterns of use of antithrombotic therapy and quality of anticoagulation among patients with non-valvular atrial fibrillation in clinical practice. Int J Clin Pract 2006;60:258-64